secwatch.observer — SEC 8-K summary
======================================

Issuer:     STRATA Skin Sciences, Inc. (SSKN)
CIK:        0001051514
Form:       8-K
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0001140361-23-053319
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

STRATA Skin Sciences Q3 revenue down 6% to $8.9M; suspends FY 2023 guidance
---------------------------------------------------------------------------

- Total revenues $8.9M vs $9.4M in Q3 2022 (-6.0%); global recurring rev $5.3M vs $5.8M.
- Net loss $1.1M ($0.03 loss per share) vs $1.0M loss in Q3 2022.
- Non-GAAP EBITDA improved to $1.0M from $0.6M; gross margin fell to 56% from 62%.
- Company suspends FY 2023 guidance following management change effective Oct 31, 2023.
- Dr. Dolev Rafaeli named CEO and Vice-Chairman, effective October 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1051514/000114036123053319/0001140361-23-053319-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1051514/000114036123053319/ef20014656_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-053319

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer